Evidence map›Paper›PMID 38467981›Full record

ArticleAdvances in experimental medicine and biology2024

Molecular Imaging of PD-1 Unveils Unknown Characteristics of PD-1 Itself by Visualizing "PD-1 Microclusters".

Wataru Nishi, Ei Wakamatsu, Hiroaki Machiyama, Ryohei Matsushima, Yosuke Yoshida, Tetsushi Nishikawa, Hiroko Toyota, Masae Furuhata, Hitoshi Nishijima, Arata Takeuchi and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in experimental medicine and biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Wataru NishiDepartment of Thoracic Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Ei WakamatsuDepartment of Immunology, Tokyo Medical University, Tokyo, Japan.
Hiroaki MachiyamaDepartment of Immunology, Tokyo Medical University, Tokyo, Japan.
Ryohei MatsushimaDepartment of Thoracic Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Yosuke YoshidaDepartment of Immunology, Tokyo Medical University, Tokyo, Japan.
Tetsushi NishikawaDepartment of Immunology, Tokyo Medical University, Tokyo, Japan.
Hiroko ToyotaDepartment of Immunology, Tokyo Medical University, Tokyo, Japan.
Masae FuruhataDepartment of Immunology, Tokyo Medical University, Tokyo, Japan.
Hitoshi NishijimaDepartment of Immunology, Tokyo Medical University, Tokyo, Japan.
Arata TakeuchiDepartment of Immunology, Tokyo Medical University, Tokyo, Japan.
Makoto SuzukiDepartment of Thoracic Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Tadashi YokosukaDepartment of Immunology, Tokyo Medical University, Tokyo, Japan. yokosuka@tokyo-med.ac.jp.
Tokyo Medical University · JPKumamoto University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Programmed cell death-1 (PD-1) is one of the most famous coinhibitory receptors that are expressed on effector T cells to regulate their function. The PD-1 ligands, PD-L1 and PD-L2, are expressed by various cells throughout the body at steady state and their expression was further regulated within different pathological conditions such as tumor-bearing and chronic inflammatory diseases. In recent years, immune checkpoint inhibitor (ICI) therapies with anti-PD-1 or anti-PD-L1 has become a standard treatment for various malignancies and has shown remarkable antitumor effects. Since the discovery of PD-1 in 1992, a huge number of studies have been conducted to elucidate the function of PD-1. Herein, this paper provides an overview of PD-1 biological findings and sheds some light on the current technology for molecular imaging of PD-1.

Indexed as

NeoplasmsProgrammed Cell Death 1 ReceptorB7-H1 AntigenHumansImmunotherapyMolecular ImagingT-LymphocytesB7-H1 AntigenProgrammed Cell Death 1 ReceptorICIImmune checkpointImmune checkpoint inhibitorImmunological synapseMicroclusterMolecular imagingPD-1Programmed cell death 1T cell signalingTumor immunotherapy

Identifiers

PMID38467981
OpenAlexW4392711666

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.